Effects of Rivastigmine on Cognitive Function and Quality of Life in Patients with Schizophrenia

Clinical Neuropharmacology

Volumn 26, Issue 6, 2003, Pages 317-321

  Lenzi, Alessandro ^a   Maltinti, Elisabetta ^a   Poggi, Enzo ^a   Fabrizio, Lazzerini ^a   Coli, Elisabetta ^a  

^a Clinica Psichiatrica   (Italy)

Author keywords

Attention; Cholinesterase inhibition; Psychosis; Quality of life; Rivastigmine; Schizophrenia

Indexed keywords

CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; ARTICLE; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; PSYCHOSIS; QUALITY OF LIFE; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CARBAMATES; COGNITION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 0344306578     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200311000-00011     Document Type: Article

References (29)

1. Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenia symptoms. Qual Life Res. 2003;12:1-9.
2. Davis KL, Kahn RS, Ko G, et al. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991;148:1474-1486.
3. Powchik P, Davidson M, Haroutunian V, et al. Postmortem studies in schizophrenia. Schizophr Bull. 1998;24:325-341.
4. Friedman JI, Adler DN, Howanitz E, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol Psychiatry. 2002; 51:349-357.
5. MacEwan GW, Ehmann TS, Khanbhai I, et al. Donepezil in schizophrenia - is it helpful? An experimental design case study. Acta Psychiatr Scand. 2001;104:469-472.
6. Risch SC, McGurk S, Horner MD, et al. A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: functional MRI correlates. Neurocase. 2001;7:105-110.
7. Rosse RB, Deutsch SI. Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia. Clin Neuropharmacol. 2002;25:272-275.
8. Kirrane RM, Mitropoulou V, Nunn M, et al. Physostigmine and cognition in schizotypal personality disorder. Schizophr Res. 2001;48: 1-5.
9. Darvesh S, MacKnight C, Rockwood K. Butyrylcholinesterase and cognitive function. Int Psychogeriatr. 2001;13:461-464.
10. Mesulam M, Guillozet A, Shaw P, et al. Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain. Neurobiol Dis. 2002;9:88-93.
11. Ballard CG. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur Neurol. 2002;47:64-70.
12. Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin. 2001;17:1-7.
13. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract 2002;Suppl 127:6-19.
14. th edition. Washington DC: American Psychiatric Association, 1994.
15. Baker F, Intagliata J.: Quality of life in the evaluation of community support systems. Eval Program Plann. 1982;5(1)
16. Folstein M, Folstein S, McHugh P. Mini-Mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
17. Riccio CA, Reynolds CR, Lowe PA. Clinical Applications of Continuous Performance Tests: Measuring Attention and Impulsive Responding in Children and Adults. Chichester, UK: John Wiley & Sons Ltd 2001; 408 pp.
18. Wechsler D. Wechsler Memory Scale Forma 1, Manuale di Istuzioni OS Firenzi, 1975.
19. Hafkenscheid A. Reliability of a standardized and expanded Brief Psychiatric Rating Scale: a replication study. Acta Psychiatr Scand. 1993;88:305-310.
20. st Annual Meeting of the Canadian Psychiatric Association, Montreal, Canada, 15-19 November 2001.
21. Trepanier S, Panisset M. Donepezil in patients with Parkinson's disease and dementia. Poster presented at the 37th Annual Meeting of the Canadian Congress of Neurological Sciences, Vancouver, Canada, 18-22 June 2002.
22. Stryjer R, Strous RD, Bar F, et al. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Clin Neuropharmacol. 2003;26:12-17.
23. McKeith I, Truyen L, Lilienfeld S, et al. The long-term treatment response in patients with moderate-to-severe Alzheimer's disease: galantamine vs donepezil. Neurology. 2003;60(Suppl 1):A141.
24. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16:1171-1174.
25. Weiser M, Rotmensch HH, Korczyn AD, et al. A pilot, randomized, open label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioural disturbances. Int J Geriatr Psychiatry. 2002; 17:343-346.
26. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr Med Res Opin. 2002;18:258-264.
27. Fogelson N, Kogan E, Korczyn AD, et al. Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. Acta Neurol Scand. 2003;107:252-255.
28. Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry. 1986;143: 1155-1158.
29. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-247.